L’Oréal/Body Shop deal
This article was originally published in The Rose Sheet
Executive Summary
French company's offer to The Body Shop shareholders has been extended to May 31, firm announces May 4. As of May 3, the original closing date of the offer, company had received acceptances amounting to 172,793,857 shares, representing 79.44% of Body Shop existing issued ordinary shares. L'Oréal now holds 195,593,857 shares, or 89.92% of existing issued ordinary shares, when including the 22,800,000 shares already acquired (1"The Rose Sheet" March 27, 2006, In Brief). L'Oréal announced its proposed $1.15 bil. purchase of British retailer in March (2"The Rose Sheet" March 20, 2006, p. 3)...
You may also be interested in...
L’Oréal/Body Shop
French beauty company has purchased 22,800,000 ordinary shares in The Body Shop International PLC, giving L'Oréal a majority stake in UK-based retail chain, firm announces March 23. "These shares, together with the shares that are the subject of the irrevocable undertakings and the call option detailed" in the company's March 17 announcement of The Body Shop acquisition, "will result in L'Oréal holding approximately 53.1% of the existing issued share capital," firm says. L'Oréal is acquiring The Body Shop for $1.15 bil. in cash (1"The Rose Sheet" March 20, 2006, p. 3)...
L’Oréal Plans To Acquire The Body Shop In $1.15 Bil. Deal
L'Oréal's planned acquisition of British retailer The Body Shop adds a "masstige" retail element to the French firm's portfolio, while giving The Body Shop access to L'Oréal's extensive research and development capabilities, the firms said March 17
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.